The varicella vaccines market is estimated to reach USD 3,258.6 million in 2024. It is estimated that revenue will increase at a CAGR of 2.4% between 2024 and 2034. The market is anticipated to reach USD 4,115.4 million by 2034.
Public health campaigns and government initiatives have resulted in increased awareness about the effectiveness of vaccination against varicella. The rising incidence of varicella infections, particularly in densely populated areas, further propels demand for vaccination.
Additionally, the development of combination vaccines that include varicella alongside other immunizations enhances convenience for parents and increases compliance. In Contrast the Monovalent Vaccine have been contributing the large share of revenue due to reduced tendency for side effect. These vaccines have been included in the immunization program by many countries to prevent the spread of Chickenpox and Herpes Zoster.
Varicella Vaccines Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 3,183.4 million |
| Estimated Size, 2024 | USD 3,258.6 million |
| Projected Size, 2034 | USD 4,115.4 million |
| Value-based CAGR (2024 to 2034) | 2.4% |
The varicella vaccine market has been influenced by increasing awareness and government initiatives. Major public health campaigns, with the help of organizations such as WHO and CDC, have successfully communicated the advantages of varicella vaccination to many high-income countries incorporating the varicella vaccination into their standard immunization schedules. This proactive approach has ensured a drastic reduction in chickenpox cases.
With increasing international travel and migration, varicella vaccination has also become a growing concern among travelers and migrants coming from countries with low vaccination coverage. These migrant with infection can spread it to vulnerable individuals in countries with high vaccination coverage.
Combination vaccines have become more popular recently because they result in a reduced number of injections. This improved the adherence to the vaccine schedule and improved the overall coverage. On the other hand, monovalent vaccine has been dominating the market because of their reduced side effect and strong antibody reaction.
Which lead to activity for long period. Also, the risk of varicella is greater in older patients. Hence as the population increases the need for adult immunization also increases. Hence the aforementioned factors are driving the market growth.
The high price of vaccines puts a drag on market growth in countries with low healthcare expenditures. A low perception of varicella as a significant pathogen will translate to minimal priority given to vaccination against the disease. All in all, growing awareness, governmental support, and changeable healthcare dynamics would serve as growth factors for the varicella vaccine market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The above table presents the expected CAGR for the global varicella vaccines market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 3.4%, followed by a slightly lower growth rate of 3.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 3.4% (2023 to 2033) |
| H2 | 3.0% (2023 to 2033) |
| H1 | 2.4% (2024 to 2034) |
| H2 | 2.1% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 2.4% in the first half and remain relatively moderate at 2.1% in the second half. In the first half (H1) the market witnessed a decrease of 100 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Increased Awareness and Government Initiatives have fueled the Varicella Vaccines Market growth
Awareness about the benefits accruing from varicella vaccination has resulted from extensive public health campaigns. The importance of varicella vaccine is abundantly highlighted by the WHO and CDC. WHO’s Global Vaccine Action Plan states that vaccination is considered one of the most effective ways to control and eventually eradicate a series of vaccine-preventable diseases.
Thus, chickenpox was defined as a priority disease. The CDC reports that since the introduction of the varicella vaccination program, there has been a reduction in chicken pox cases by 90 percent in the United States alone and ascertains that the vaccine is effective hence encouraging other countries to do the same as far as vaccination against the disease is concerned.
This has turned this varicella vaccine into a routine one in the schedule of immunization during childhood in many high-income countries. Conditions of unimmunized or under-immunized adults or those at higher risk-like healthcare workers and the immunocompromised have raised more interest in adult vaccination.
It is further put into evidence by data showing the much more serious potential complications of chickenpox in adults: severe pneumonia, encephalitis, and secondary bacterial infections. Accordingly, it is due to increased awareness and efforts by the government that the boom in the market has been observed.
Increased Global Travel and Migration Contribute to the Spread of Varicella and drives demand for Varicella Vaccines
The risk of spread of infectious diseases like varicella among populations moving from areas of low vaccination coverage to areas of higher vulnerability increases manifold. When such people visit or migrate to other countries with higher vaccination coverage, they may be unaware of their action of carrying the virus into communities, particularly among unvaccinated or immunocompromised persons.
These facts have also created an increasing awareness of the need to ensure varicella vaccination for travelers and migrants before entering countries where the disease has been well controlled.
Supporting data is emphasized to show that international travel plays a conducive role in the transmission of varicella. For instance, the European Centre for Disease Prevention and Control reported the increasing reporting of imported varicella and other vaccine-preventable diseases in Europe, where travel exposure was noted to be a major factor.
WHO has reiterated the importance of vaccination among international travelers, especially those who migrate into or from areas with different vaccine coverage. The guidelines by the WHO on International Travel and Health recommend the vaccination of travelers against varicella, among others, to prevent border-to-border transmission of infection.
This increasing awareness of the threat therefore served to raise demand for the varicella vaccine, especially for international travelers and migrants, which in turn continued to drive market growth.
Increased preference for Combination Vaccines Provides an Opportunity for Market Growth
Administering the varicella vaccine in a combination vaccine simplifies the process for the doctors. It improved the adherence to the vaccination schedule. The main advantages of combination vaccines are a reduction in the number of injections given to a child.
The CDC recommends multiple vaccinations for children before they attain the age of two years, which means many injections may be administered if the vaccines are taken individually. Combination vaccines, such as MMRV, reduce the number of injections and, subsequently, the physical and psychological trauma for children and parents.
A reduction in the number of injections has been associated with improved adherence to vaccination schedules, which is crucial to sustaining high immunization rates and acquiring herd immunity. According to a study published in the Journal of Public Health, after the introduction of MMRV at 18 months, varicella coverage increased by 4%.
With that said and done, therefore, this more or less suggests that combination vaccines could just be the absolute game changer in increasing vaccination rates, especially in settings or regions where vaccine hesitancy and/or logistical challenges could otherwise hold back coverage.
Economic benefits also favor market growth for combination vaccines. Combining several vaccinations into one single shot cuts down the cost of storage and transportation of vaccines, and administration within healthcare systems.
High Vaccine Cost can hinder the Market Growth
The associated cost of the vaccine, which includes production, storage, transportation, and administration costs, is restricting varicella vaccine accessibility, especially in areas where healthcare budgets are limited.
This issue is further exacerbated by the fact that, although it can be a serious disease, varicella is not often perceived to be life-threatening and thus tends to receive generally lower prioritization for vaccination in public and private healthcare.
According to the WHO Report, the median price, in USD per dose for self-procuring high-income countries, increased from USD 25.35 in 2019 to USD 35.80 in 2021. This upward trend in price serves as an alarming signal.
For example, in countries like India and parts of Africa, where the majority section of the population lives below the poverty line, spending on precautionary healthcare such as vaccination is usually compromised to address more urgent health needs.
Besides, the cost of vaccination programs for infrastructural investment in cold chain management, training of staff, and public awareness programs is an added financial burden on health systems. Resource-limited governments and health care providers cannot afford to provide enough funding to support widespread varicella vaccination programs, leading to overall lower coverage rates.
Certain African countries, where healthcare expenditure is required to increase significantly for the introduction of varicella vaccines, often depend on external funding or subsidy. Hence, high costs of vaccines and inflated pricing further escalate the prices, acting as an obstacle to this market.
Principal Consultant
The varicella vaccines industry recorded a CAGR of 2.4% between 2019 and 2023. According to the industry, varicella vaccines generated USD 3,183.4 million in 2023, up from USD 2,570.0 million in 2019.
Varicella vaccination programs have been adopted with quite considerable variability among countries, driven by public health priorities, the burden of disease, and healthcare infrastructure. The United States was the first country to adopt universal varicella vaccination in 1995.
Further, Canada adopted similar measures following the United States, reinforcing vaccination in childhood immunization schedules. In Asia, Japan, where the varicella vaccine was first invented, has been very slow to introduce universal vaccination despite licensing the vaccine in 1987.
On the other hand, South Korea implemented universal varicella vaccination in 1988. Other new emerging markets like Brazil and Uruguay have also chosen to opt for universal vaccination. The Europeans, until now, have been more circumspect, for instance, targeted vaccination rather than universal programs in Germany and parts of Italy.
This variability is influenced by concerns about potential shifts in disease incidence to older populations and the economic implications of widespread vaccination.
Over the recent past, Combination Vaccines have become more preferred. According to the report from PATH, national stakeholders and healthcare providers in low and middle-income countries have a strong preference for combination vaccines over stand-alone vaccines.
The convenience of administering many vaccines in one injection, thus simplifying logistics and reducing the number of visits made by caregivers with children to healthcare facilities, is one factor driving this preference. For this reason, combination vaccines are considered one of the means of improving not only rates of coverage but, more importantly, overall coverage in relation to improving public health outcomes.
Companies in the Tier 1 sector account for 60.9% of the global market, ranking them as the dominant players in the industry. Tier 1 players offer a wide range of products related to research laboratories, have an established industry presence, offer continuous innovation, and have a significant influence in the field.
Having financial resources that enables them to enhance their research and development efforts and expand into new markets. A strong brand recognition and a loyal customer base provide them with a competitive advantage. Prominent companies within Tier 1 include GlaxoSmithKline PLC, Merck & Co. Inc., and GC Pharma (Green Cross Holdings).
Tier 2 players dominate the industry with a 28.9% market share. Tier 2 firms have a strong focus on a specific technology and a substantial presence in the industry, but they have less influence than Tier 1 firms. The players are more competitive when it comes to pricing and target niche markets.
New products and services will also be introduced into the industry by Tier 2 companies. Tier 2 companies include Bio-Med Pvt Ltd, Novo Medi Sciences Pvt Ltd, and Takeda Pharmaceutical Company Limited among others.
Compared to Tiers 1 and 2, Tier 3 companies have smaller revenue spouts and less influence. Those in Tier 3 have smaller work force and limited presence across the globe. Prominent players in the tier 3 category are Mitsubishi Tanabe Pharma Corporation, Sinovac Biotech Ltd., Changchun Keygen Biological Products Co., Ltd (CNBG Subsidiary), Sinergium Biotech, and SK Bioscience Co., Ltd.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the varicella vaccine market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia, Western Europe, Eastern Europe, and Middle East and Africa (MEA), is provided.
The United States is anticipated to remain at the forefront in North America through 2034. India is projected to witness a CAGR of 2.4% from 2024 to 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 1.3% |
| Germany | 1.6% |
| France | 1.5% |
| Italy | 1.3% |
| China | 2.8% |
| India | 2.5% |
| Japan | 1.7% |
The sales of varicella vaccines is expected to grow at a 1.5% CAGR over the forecast years. The strong healthcare infrastructure United States leads to effective distribution of the varicella vaccine. Public health campaigns also enhance market growth.
As per Centers for Disease Control and Prevention, vaccination promotions are done as a part of preventive measure to reduce the incidence of this disease. The Public Health Accreditation Board estimates 3.5 million cases & more in the United States with 9,000 hospitalization admission, and about 100 deaths are prevented because of varicella vaccination.
The contribution of the USA government went to increasing the immunization. Under the operation Allies Welcome campaigns, 49,000 Afghan refugees received vaccinations against measles, mumps, and rubella, varicella-chicken pox. Increasing awareness and access ensures higher participation in the immunization programs due to the government.
The market is growing in the United States due to strong healthcare infrastructure coupled with effective government initiatives and campaigns related to public health.
Varicella Vaccines market is predicted to grow at a rate of 2.8% over the forecast years. The Chinese government has been undertaking active vaccinations for infectious diseases, one of which includes chickenpox, a disease that conventionally involves large populations.
This is very important because China, being a hugely populated country, may consider that the incidence of varicella could lead to considerable public health challenges. According to China's National Institutes for Food and Drug Control, the total number of doses of all kinds of vaccines, inclusive of the varicella vaccine, approved in China, has risen from USD 36.01 million in 2016 to USD 73.08 million in 2020.
More and more families have realized the benefits from vaccination, and there has been an improvement in uptake with support from health education by the health authorities. It is complemented by improved health infrastructure in rural areas, contributing to better access to vaccines.
A well prone-disease environment contributes significantly to higher vaccination rates. More importantly, international organizations and local healthcare authorities are working to improve the affordability and availability of vaccines, increasing market demand. These are some of the factors that make China a major contributor to the growing varicella vaccine market.
The improved awareness of the varicella vaccine, especially the incidence of herpes zoster, which is becoming more prominent with an aging population, raised the need for effective vaccination against the diseases stemming from chickenpox and shingles.
Increasing awareness of demographic health risks attributed to infections from the varicella-zoster virus has increased the call for vigorous varicella vaccination not only by public health officials but also by health service providers.
The healthcare system in Japan also encourages preventive care; hence, the government recommends varicella vaccination in children and adults. These proactive drives are powered by firmly rooted immunization policies that target high immunization coverage, and coverage has proven to prevent outbreak of the disease.
The Japanese public also attained a high level of consciousness with regard to vaccination, as evidenced by increased rates of acceptance to education among others boosting campaigns on safety and effectiveness associated with the varicella vaccine.
The market is also supported by the introduction of new vaccines and continuing enhancement of healthcare access, especially in the urban population. Between 2024 and 2034, Japan is expected to expand at a CAGR of 1.7%.
A description of the leading segments in the industry is provided in this section. The monovalent varicella segment held 67.2% of the value share in 2024. Based on the application, chickenpox immunization held 62.3% of the market in 2024.
| Application | Monovalent Varicella |
|---|---|
| Value Share (2024) | 67.2% |
Combined vaccine such as measles, mumps, rubella, and varicella (MMRV) has higher risk of febrile Seizure in children compared to the MMR and V administered during the same medical visit.
The febrile seizure is common side effect within the children receiving any vaccine. Hence the lower risk of same from monovalent varicella vaccine make it an appealing option. Also monovalent varicella vaccine tends to induce long-lasting antibody response. Which can be around 10 years.
Monovalent varicella vaccines are a part of routine children immunization program within many countries. This government led immunization program are a major factor in the large scale adoption of monovalent varicella vaccines. Monovalent vaccines are used for immunization against Chickenpox and Herpes Zoster both, which makes it preferred choice.
The combined factor of reduced risk profile, strong antibody response, involvement in government programs, and effectiveness against the wide spectrum of pathogen have resulted in the dominance of monovalent varicella vaccines.
| Capacity | Chickenpox Immunization |
|---|---|
| Value Share (2024) | 39.6% |
Chickenpox is caused by varicella zoster virus. Since this disease is more common among children, most governments have introduced effective immunization programs towards prevention of this disease. This program ensures vaccines are offered either at subsidized or free cost, thereby encouraging more adoption of the varicella vaccines.
Greater awareness through education campaigns has also led to increased public trust in the safety and effectiveness of vaccines. According to the WHO report published in 2023, the global burden of chickenpox was about 140 million cases. While the global burden of herpes zoster reported in 2019 was around 84 million.
Rising investment in research and development has eventually gave a way to new vaccines. Hence, Chickenpox immunization accounts for the largest share, due to contagious nature, high prevalence, rising awareness, and R&D funding dominance.
Market players are collaborating with other industry players to augment each other’s research capability and develop novel vaccine. After the completion of a successful partnership most of the time the organizations extend the partnership program further.
Another critical area of focus is the regulatory approval process. Companies are striving to get their vaccine approved in the major market to increase their revenue stream. In order to tackle the competition large market players, acquire the small emerging biotech firm. This increases the RD portfolio of the company and help them address the upcoming competitions.
Recent Industry Developments in the Varicella Vaccines Market
In terms of product, the industry is segmented into monovalent vaccine and combination vaccine.
In terms of application, the industry is bifurcated into chickenpox immunization and herpes zoster immunization.
In terms of end users, the industry is segregated into hospitals, clinics, and others.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, the Middle East, and Africa have been covered in the report.
Varicella Vaccines industry is expected to increase at a CAGR of 2.4% between 2024 and 2034.
The diabetes segment is expected to occupy a 67.2% market share in 2024.
The global varicella vaccines market is predicted to procure USD 5.76 Billion from 2022 to 2032.
The United States is forecast to see a CAGR of 1.5% during the assessment period.
The key players in the varicella vaccines industry include GlaxoSmithKline PLC, Merck & Co. Inc., GC Pharma (Green Cross Holdings), Bio-Med Pvt Ltd, Novo Medi Sciences Pvt Ltd, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Sinovac Biotech Ltd., Changchun Keygen Biological Products Co., Ltd (CNBG Subsidiary), Sinergium Biotech, and SK Bioscience Co., Ltd.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Pricing Analysis 5. Global Market Size Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. By Product 6.2. By Application 6.3. By End User 6.4. By Region 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Product 7.1. Monovalent Vaccine 7.2. Combination Vaccine 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application 8.1. Chickenpox Immunization 8.2. Herpes Zoster Immunization 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 9.1. Hospitals 9.2. Clinics 9.3. Others 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. East Asia 10.4. South Asia and Pacific 10.5. Western Europe 10.6. Eastern Europe 10.7. Middle East and Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Product, and Application for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. GlaxoSmithKline PLC 20.2. Merck & Co. Inc. 20.3. GC Pharma (Green Cross Holdings) 20.4. Bio-Med Pvt Ltd 20.5. Novo Medi Sciences Pvt Ltd 20.6. Takeda Pharmaceutical Company Limited 20.7. Mitsubishi Tanabe Pharma Corporation 20.8. Sinovac Biotech Ltd. 20.9. Changchun Keygen Biological Products Co., Ltd (CNBG Subsidiary) 20.10. Sinergium Biotech 20.11. SK Bioscience Co., Ltd.
Explore Healthcare Insights
View Reports
Varicella Vaccines Market
